Skip to main content

Human breast cancer: survival from first metastasis

Breast Cancer Research and Treatment volume 21, pages 173–180 (1992)Cite this article

Summary

Survival from the detection of first metastasis (SAM) was analyzed in a single center series of 258 patients with advanced breast cancer. During the 15 year period covered by this study 230 patients died, 215 of their disease. The overall median SAM was 28 months.

Univariate analysis of SAM stratified by first dominant site of metastasis, estrogen receptor status (ER), progesterone receptor status (PgR), tumor size, axillary lymph node status, patient age, menopausal status, and disease-free interval (DFI) showed the first dominant site of metastasis, ER, PgR, and axillary lymph node status to be significantly associated with SAM. Patients with visceral metastasis as first dominant site of metastasis had significantly shorter survival than those with either bone or soft tissue metastasis, median SAM 16 vs. 34 vs. 41 months respectively (P<0.001). SAM also differed according to the steroid hormone receptor status of the primary tumor: median SAM 34 and 33 months for patients with ER-positive or patients with PgR-positive tumors against 14 months for patients with ER-negative or with PgR-negative tumors (P<0.001). Patients with axillary lymph node involvement at primary disease had a shorter SAM than those without, median SAM 24 vs. 35 months (P=0.006). No association between SAM and either tumor size, patient age, menopausal status, or DFI could be observed.

Multivariate analysis including first dominant site of metastasis, ER, PgR, and axillary lymph node status showed the first dominant site of metastasis, ER, and axillary lymph node status to be independently associated with SAM.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Koenders PG, Beex LVAM, Langens R, Kloppenborg PWC, Smals AGH, Benraad ThJ, the Breast Cancer Study Group: Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. Breast Cancer Res Treat 18: 27–32, 1991

    PubMed  Google Scholar 

  2. EORTC Breast Cancer Co-operative Group: Revision of standards for the assessment of hormone receptors in human breast cancer: Report of the second EORTC workshop. Eur J Cancer 16: 1513–1515, 1980

    Google Scholar 

  3. SAS (Statistical analyzing system) User's Guide: Statistics, version 5 edition. SAS Institute Inc., Box 8000, Cary, NC 27511-8000

  4. Shimkin MB, Lucia EL, Low-Beer BVA, Bell HG: Recurrent cancer of the breast. Cancer 7: 29–46, 1953

    Google Scholar 

  5. Cutler SJ, Asire AJ, Taylor SG: Classification of patients with disseminated cancer of the breast. Cancer 24: 861–869, 1969

    PubMed  Google Scholar 

  6. Clark GM, Sledge GW, Osborne CK, McGuire WL: Survival from first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5: 55–61, 1987

    PubMed  Google Scholar 

  7. Hähnel R, Woodings T, Brian A: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44: 671–675, 1979

    PubMed  Google Scholar 

  8. Campbell FC, Blamey RW, Elston CW, Nicholson RI, Griffiths K, Haybittle JL: Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer 44: 456–459, 1981

    PubMed  Google Scholar 

  9. Stewart JF, King RJB, Sexton SA, Millis RR, Rubens RD, Hayward JL: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17: 449–453, 1981

    PubMed  Google Scholar 

  10. Paterson AHG, Zuck VP, Szafran O, Lees AW, Hanson J: Influence and significance of certain prognostic factors on survival of breast cancer. Eur J Can Clin Oncol 18: 937–943, 1982

    Article  Google Scholar 

  11. Howell A, Harland RNL, Bramwell VHC, Swindell R, Barnes DM, Redford J, Wilkinson MJS, Crowther D: Steroid hormone receptors and survival after first relapse in breast cancer. Lancet i: 588–591, 1984

    Article  Google Scholar 

  12. Howat JMT, Harris M, Swindell R, Barnes DM: The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer 51: 263–270, 1985

    PubMed  Google Scholar 

  13. Alexieva-Figusch J, van Putten WLJ, Blankenstein MA, van den Blonk-Wijst J, Klijn JGM: The prognostic value and relationships of patients characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 61: 758–768, 1988

    PubMed  Google Scholar 

  14. Shek LLM, Godolphin W: Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 48: 5565–5569, 1988

    PubMed  Google Scholar 

  15. Kamby C, Bruun Rasmussen B, Kirstensen B: Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 60: 253–257, 1989

    Google Scholar 

  16. Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P: Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological grading. Br J Cancer 62: 142–146, 1990

    PubMed  Google Scholar 

  17. Tinnemans JGM, Beex LVAM, Wobbes Th, van de Sluis RF, Raemaekers JMM, Benraad ThJ: Steroid-hormone receptors in nonpalpable and more advanced stages of breast cancer; a contribution to the biology and natural history of carcinoma of the female breast. Cancer 66: 1165–1167, 1990

    PubMed  Google Scholar 

  18. Raemaekers JM, Beex LVAM, Pieters GFFM, Smals AGH, Benraad ThJ, Kloppenborg PWC, the Breast Cancer Study Group: Progesterone receptor activity and the response to the first endocrine therapy in advanced breast cancer. Eur J Can Clin Oncol 23: 443–448, 1987

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medicine, Division of Endocrinology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands

    P. G. Koenders, L. V. A. M. Beex, P. W. C. Kloppenborg & A. G. H. Smals

  2. Department of Experimental and Chemical Endocrinology, University Hospital Nijmegen, Nijmegen, The Netherlands

    P. G. Koenders & Th. J. Benraad

Authors
  1. P. G. Koenders
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. V. A. M. Beex
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. W. C. Kloppenborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. G. H. Smals
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Th. J. Benraad
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the Breast Cancer Study Group

Additional information

including the Departments of Surgery (Th. Wobbes, R.F. v.d. Sluis), Radiotherapy (W.A.J. v. Daal), Pathology (R. Holland), Radiology (J.H.C.L. Hendriks) and Medical Oncology (D. Wagener)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Koenders, P.G., Beex, L.V.A.M., Kloppenborg, P.W.C. et al. Human breast cancer: survival from first metastasis. Breast Cancer Res Tr 21, 173–180 (1992). https://doi.org/10.1007/BF01975000

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01975000

Key words

  • breast cancer
  • site of first metastasis
  • survival
  • nodal status
  • estrogen receptors
  • progesterone receptors
  • prognosis